Overview

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of two dose regimens of TP-434 compared with ertapenem in the treatment of adult community-acquired complicated intra-abdominal infections (cIAIs).
Phase:
Phase 2
Details
Lead Sponsor:
Tetraphase Pharmaceuticals, Inc.
Treatments:
Ertapenem